Washington Dc, DCNCT05925803Now EnrollingIRB Ready

Scleroderma Clinical Trial in Washington Dc, DC

Access cutting-edge scleroderma treatment through this clinical trial at a research site in Washington Dc. Study-provided care at no cost to qualified participants.

Sponsored by AstraZeneca

Quick Self-Assessment

See if you qualify for this Washington Dc location

Preparing your pre-screening questions...

Expert Care in Washington Dc

Access scleroderma specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related scleroderma treatment provided free

Apply for This Washington Dc Location

Check if you qualify for this scleroderma clinical trial in Washington Dc, DC

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Washington Dc

    Convenient for DC residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Washington Dc site if eligible
  4. 4Begin participation

About This Scleroderma Study in Washington Dc

The purpose of this study is to evaluate the efficacy and safety of treatment with subcutaneous anifrolumab versus placebo in adult participants with systemic sclerosis. The target population for this study includes patients who meet the 2013 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) classification for systemic sclerosis, either limited or diffuse cutaneous subsets, with a disease duration of less than 6 years from first non-Raynaud's phenomenon symptom.

Sponsor: AstraZeneca

Who Can Participate

Inclusion Criteria

Adult patients from 18 to 70 years of age inclusive 2. Systemic sclerosis according to 2013 ACR/EULAR classification criteria 3. Limited or diffuse cutaneous subsets 4. Systemic sclerosis disease duration within 6 years from first non-Raynaud's phenomenon manifestation at the time of signing the ICF 5. Either HAQ-DI score ≥ 0.25 points or PtGA score ≥ 3 points 6. mRSS \> 10 with early disease or rapid progression as defined by the protocol 7. mRSS ≥ 15 with disease duration ≥ 18 months and active disease as defined by the protocol 8. Stable background therapies can be used including hydroxychloroquine, methotrexate, azathioprine, mycophenolate mofetil, mycophenolate sodium, mycophenolic acid, oral glucocorticoids or tacrolimus 9. Women of childbearing potential with a negative urine pregnancy test 10. Uninvolved skin at injection sites Key

Exclusion Criteria

Anticentromere antibody seropositivity on central laboratory 2. Severe cardiopulmonary disease

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Washington Dc?

Yes, this clinical trial (NCT05925803) has an active research site in Washington Dc, DC that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Scleroderma Treatment Options in Washington Dc, DC

If you're searching for scleroderma treatment options in Washington Dc, DC, this clinical trial (NCT05925803) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Washington Dc research site is actively enrolling participants for this clinical trial. You'll receive care from experienced scleroderma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all scleroderma clinical trials near you to find additional studies recruiting in your area.

More Scleroderma Trials in Washington Dc, DC

See all scleroderma clinical trials recruiting in Washington Dc — not just this study.

Browse Scleroderma Trials in Washington Dc →

Browse More Trials by Condition

Scleroderma TrialsAll Conditions →

Ready to Join in Washington Dc?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Washington Dc, DC